The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
The company’s total income jumped 31% year-on-year to Rs 125.5 crore
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
The base Gland business posted ?11,790 million in revenue, up 16% YoY
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
Subscribe To Our Newsletter & Stay Updated
